KEY PONTIFICATION: The all front attack against pharma drug pricing is going to de very little to lower overall healthcare costs but politicians are not about providing REAL results, they are all about getting re-elected. Pharma companies largely ignored the gathering storm clouds and went about business as usual which is resulting in new restrictions that are going to limit innovation.

  • Edelman’s annual trust barometer research recorded an increase of 6 points in the U.S. that helped pharma reach a new rating score of 44.
  • The industry would need to reach 50 to get to neutral territory and to 60 to be considered trusted under the Edelman ratings.
  • Overall, trust in healthcare—which includes pharma, biotech and life sciences, hospitals and clinics, insurance and consumer health—increased by 8 points in the U.S. to reach 61.